SOUTH SAN FRANCISCO - Genentech, a member of the Roche Group, announced Monday it will present data from nine approved and investigational medicines across more than 15 indications at the 2026 American Society of Clinical Oncology Annual Meeting, scheduled for May 29 to June 2 in Chicago.
The company will focus on giredestrant, an investigational oral selective estrogen receptor degrader being studied in early and advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. This subtype accounts for approximately 70% of breast cancer cases.
Data from three Phase III trials will be presented. The lidERA study will show whether efficacy and safety of giredestrant remain consistent across pre- and post-menopausal patients with early breast cancer. The company previously reported in December 2025 that the study demonstrated a 30% reduction in the risk of invasive disease recurrence or death. The lidERA data have been submitted to the U.S. Food and Drug Administration.
The persevERA study will present primary results investigating giredestrant in combination with palbociclib as a first-line therapy in locally advanced or metastatic cancer. The study did not meet its primary endpoint, though the combination showed a numerical improvement in progression-free survival.
The evERA study will share post-progression treatment analyses exploring clinical benefit for people treated with giredestrant plus everolimus. The FDA recently accepted the New Drug Application for giredestrant based on the positive evERA data.
Genentech will also present preliminary results from a Phase Ic expansion trial of ZN-A-1041, a blood-brain barrier-permeable HER2-selective tyrosine kinase inhibitor, in combination with other HER2-targeted therapies for patients with pre-treated HER2-positive metastatic breast cancer.
Additional presentations will include data on divarasib in non-small cell lung cancer and updated results from the Phase III SUNMO trial evaluating Lunsumio plus Polivy compared to chemotherapy in second-line patients with relapsed/refractory diffuse large B-cell lymphoma.
The information is based on a press release statement from Genentech.
In other recent news, Roche's first-quarter 2026 sales are expected to be approximately 2% below Street estimates, according to Morgan Stanley. The firm anticipates a year-over-year growth of 5.7% in constant exchange rates, with a significant 10.4% foreign exchange headwind impacting results. Despite these challenges, Argus upgraded Roche's stock rating to Buy from Hold, citing an attractive valuation after a 17% decline in shares since February 2026. Argus set a price target of $55.00, presenting what they see as an appealing entry point for investors.
